58.43
前日終値:
$59.02
開ける:
$58.63
24時間の取引高:
2.15M
Relative Volume:
0.61
時価総額:
$25.90B
収益:
$2.44B
当期純損益:
$1.36B
株価収益率:
30.60
EPS:
1.9093
ネットキャッシュフロー:
$574.14M
1週間 パフォーマンス:
-0.68%
1か月 パフォーマンス:
+4.21%
6か月 パフォーマンス:
+40.19%
1年 パフォーマンス:
+58.78%
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
58.43 | 26.03B | 2.44B | 1.36B | 574.14M | 1.9093 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma stock hits all-time high at 59.73 USD - Investing.com
Renaissance Technologies LLC Buys Shares of 790,937 Royalty Pharma PLC $RPRX - MarketBeat
First Trust Advisors LP Reduces Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Current ratio of Royalty Pharma Plc Class A – HAM:RPD - TradingView
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD - TradingView
Royalty Pharma PLC (RPRX) Cash Flow - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RPRX|Royalty Pharma PLC|Price:58.730|Chg%:-0.100 - TradingKey
Royalty Pharma PLC (RPRXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Dai ichi Life Insurance Company Ltd Has $6.19 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Dorsey Asset Management LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma Plc Class A Revenue Breakdown – TRADEGATE:RPD - TradingView
Royalty Pharma PLC (RPRXN) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Shares Sold by KBC Group NV - MarketBeat
RPHC5035520 Bond Profile — Key Metrics - TradingView
ABN Amro Investment Solutions Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Earnings Dates, Call Summary & Reports - TipRanks
RPHC6166014 Bond Profile — Key Metrics - TradingView
Royalty Pharma PLC (RPRX) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RPHC5222528 Bond Profile — Key Metrics - TradingView
RPHC6166014 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5035520 Bond Risk Profile - TradingView
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237354 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Royalty Pharma PLC (RPRX) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
Royalty Pharma Plc (RPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
大文字化:
|
ボリューム (24 時間):